Dayzz Sleep App Announces Publication of the Findings From Clinical Trial to Validate Its Sleep Assessment Machine Learning Engine

June 25, 2020

Innovative sleep solution provider dayzz announced this week the results of its first clinical trial. dayzz’ machine learning engine enables assessment of common sleep disturbances using a proprietary questionnaire. The clinical trial was conducted in collaboration with the Johns Hopkins Center for Interdisciplinary Sleep Research and Education.

In the U.S., more than 30% of the adult population suffer from sleep problems, and it is estimated that 50-70 million Americans have a sleep disorder that affects their health and quality of life. Many of them are undiagnosed and untreated. Insufficient sleep alone costs the US economy over $400 billion a year, and sleep problems among employees have huge financial implications on employers and payers. dayzz has developed and validated the Digital Sleep Questionnaire (DSQ) to identify common societal sleep disturbances including insomnia, delayed sleep phase syndrome, insufficient sleep syndrome, and risk for obstructive sleep apnea.

“dayzz’ machine learning algorithm was trained on gold-standard sleep expert diagnoses of people in the community with common sleep complaints and has shown high accuracy in predicting those at risk for prevalent sleep disorders,” said Dr. Mairav Cohen-Zion, Chief Science Officer at dayzz. “This is a critical step forward for dayzz in identifying sleep disorders at scale and offering a personalized sleep training experience for our users.”

In the upcoming months, dayzz will launch a randomized clinical trial in collaboration with researchers at Brigham and Women’s Hospital and Harvard Medical School to examine the effectiveness of its solution in a large community-based organizational setting. Read more here.

Sourcedayzz
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version